(±)12-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid. The biological activity of (±)12-HETE is similar to that of its constituent enantiomers (Item Nos. 34560 and 34570). It aggregates neutrophils with an EC₅₀…

An aspirin-triggered lipoxin that inhibits LTB4-induced chemotaxis, adherence, and transmigration of the neutrophils with twice the potency of LXA4 demonstrating activity in the nM range.

A bioactive macrolide derived from sponges that binds monomeric actin, preventing actin polymerization both in vitro (Kd = 0.2 μM) and in cells (0.5 μM).

A potent anti-fungal antibiotic that can directly block nuclear transport by inhibiting the action of CRM1.

A DHA-derived product first identified in mouse inflammatory exudates; reduces neutrophil infiltration in vivo in both mouse peritonitis and dermal inflammation; enhances macrophage phagocytosis and efferocytosis.

A potential metabolite of PGD2, presumably produced from the known metabolite 13,14-dihydro-15-keto PGD2.

A major CYP450 metabolite of arachidonic acid that is released from the kidney in response to angiotensin II; a potent vasodilator of renal preglomerular vessels; blocks 20-HETE-induced vasoconstriction of renal arterioles at 1 µM.

A proposed anti-inflammatory EPA metabolite that has been shown to promote inflammatory resolution in numerous disease models, including experimental colitis, asthma, atherosclerosis, type 2 diabetes, and HSV-1-induced stromal keratitis.

A potential cytochrome P450 metabolite of N-arachidonoyl taurine that may activate TRPV1 and TRPV4.

5(S)-HETrE is produced by the action of 5-LO when mead acid is the substrate. There are no literature reports of the biological activity or further metabolic fate of 5(S)-HETrE.

One of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid.

A 13R,14S-dihydroxy DHA formed by recombinant human macrophage 12-LO and sEH co-incubated with DHA; reduces neutrophil infiltration in a mouse model of peritonitis and enhances human macrophage phagocytosis of zymosan A.

15(R)-HEDE is isolated by the chromatographic resolution of (±)15-HEDE. There are no reports of biological activity associated with 15(R)-HEDE in the literature.

8(S)-HETrE is a monohydroxy PUFA produced by rabbit neutrophil lipoxygenase when DGLA is used as a substrate. Although the biological activities of 8(S)-HETrE have not been well characterized, it is expected to behave similarly to 8(S)-HETE.

A DHA epoxygenase metabolite found in rat brain and spinal cord that acts as a preferred substrate for sEH (Km = 3.2 µM); demonstrates antihyperalgesic activity in inflammatory and neuropathic pain models and potently inhibits angiogenesis and tumor growth in in vitro assays.

A positional isomer of LXA4 produced by the metabolism of 15-HETE or 15-HpETE by human leukocytes; inhibits PMV migration stimulated by LTB4 at a concentration of 10-7 M and inhibits LTB4-induced adhesion of PMNs with an IC₅₀ value of ~3 x 10-10 M.

An internal standard for the quantification of (±)14(15)-DiHET by GC- or LC-MS.

The racemic version of a CYP450 metabolite of arachidonic acid that dose-dependently stimulates vasodilation of the rabbit kidney.

The lipoxins are trihydroxy fatty acids containing a 7,9,11,13-conjugated tetraene. LXA4 was first described as a metabolite of 15-HpETE and/or 15-HETE when added in vitro to isolated human leukocytes. The material obtained in this manner consists of at least four distinct isomers: 5(S), 6(S);…

A non-enzymatic hydrolysis product of LTA4 with reduced activity compared to LTB4; also produced by oxidative decomposition of CysLTs such as LTC4 in the presence of myeloperoxidase and hypochlorous acid.

(±)11-HDHA is an autoxidation product of DHA in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. DHA is metabolized to 11(S)-HDHA by human platelets and canine retina. In addition to 11(S)-HDHA, 14(S)-HDHA is also produced by platelets.…

A purified enantiomer of (±)9-HETE resulting from non-enzymatic oxidation of arachidonic acid.

11-trans LTD4 is a C-11 double bond isomer of LTD4. LTD4 undergoes slow temperature-dependent isomerization to 11-trans LTD4 during storage. 11-trans LTD4 retains about 10-25 % of the potency for contraction of guinea pig ileum, trachea and parenchyma compared to LTD4. It exhibits an ED50 ranging…

A derivative of (±)8(9)-EET which is stable enough to ship and handle routinely.

A 5-series LO derived from EPA; contracts pulmonary parenchymal strips from guinea pig with similar potency to that of LXA4 and LXB4, yet does not exert the vasodilatory effects on aortic smooth muscle exhibited by LXA4 and LXB4.

(±)14(15)-EET-d11 contains 11 deuterium atoms at the 16, 16', 17, 17', 18, 18' ,19, 19' ,20, 20, and 20 positions. It is intended for use as an internal standard for the quantification of (±)14(15)-EET (Item No. 50651) by GC- or LC-MS.

15-OxoETE is produced by oxidation of the 15-hydroxyl of 15-HETE. Whether this is a major pathway of 15-HETE metabolism is yet to be clearly established.

(±)15-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid. The biological activity of (±)15-HETE is similar to that of its constituent enantiomers (Item Nos. 34720 and 34710).

A DHA epoxygenase metabolite detected in rat brain and spinal cord, as well as human serum, that acts as a substrate for sEH (Km = 5.1 µM); demonstrates antihyperalgesic activity in inflammatory and neuropathic pain models and potently inhibits angiogenesis and tumor growth in in vitro assays.

An epoxygenase pathway product produced from EPA by CYP450 both in vitro and in vivo; its effects of remain to be determined.

Key urinary metabolite of PGD2; represents approximately 1% and 4% of the infused radiolabeled dose in monkeys and humans, respectively.

Less potent than AEA (Item No. 90050) at the CB1 receptor (Ki = 600 versus 90 nM); inhibits FAAH.